Nucleus
Nucleus Genomics is a consumer genetics company that uses whole-genome sequencing and proprietary polygenic risk score models to sell at-home genetic tests, IVF embryo analysis software, and a $30,000 IVF concierge package to couples, IVF patients, and partner fertility clinics worldwide.
- Company typePrivate
- Founded2021
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Nucleus does
Nucleus Genomics Inc. is a New York-based consumer genetics company founded in 2021 by Kian Sadeghi that builds genetic testing products on clinical-grade whole-genome sequencing and proprietary polygenic risk score models. Its core technology sequences 1,000 times more DNA than microarray-based competitors such as 23andMe and applies a family of nine internally developed polygenic predictors — branded as Origin — to assess risk for more than 2,000 hereditary conditions and traits, including complex diseases (cancers, diabetes, heart disease, Alzheimer's), neurological conditions, and physical traits such as height, eye color, and intelligence.
The product portfolio spans Nucleus Preview and Nucleus Health (at-home cheek-swab kits with carrier screening priced in the low hundreds), Nucleus Embryo (software that analyzes up to 20 IVF embryo PGT files for prospective parents), and Nucleus IVF+ (a premium package priced at approximately $30,000 that bundles embryo analysis with fertility-clinic concierge services). An annual membership renews for ongoing model updates. Distribution combines direct-to-consumer e-commerce through mynucleus.com with a clinic-anchored IVF+ Network of more than 165 partner fertility clinics across nearly all U.S. states, India, the Middle East, and Mexico. U.S. tests are physician-ordered and reviewed through an independent physician network, with HIPAA-compliant handling and CLIA-certified lab processing.
The company is privately held and venture-backed, having raised approximately $31.5 million across a 2021 seed, a 2022 Seed+ led by Seven Seven Six, and a January 2025 Series A. In 2025 it acquired Cambrean, an Irish AI-wearable health platform, and received a strategic investment from Samsung Next to reposition toward a broader preventive health genomics platform that combines genetic baselines with continuous biometric data. The leadership team includes Founder/CEO Kian Sadeghi, CTO Varun Jana, CSO Arash Keshavarzi Arshadi, Chief Clinical Officer Nathan Treff, and COO Caio Hachem.
Nucleus firmographics
Firmographics- Name
- Nucleus
- Legal name
- Nucleus Genomics Inc.
- Website
- https://mynucleus.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nucleus Genomics is a consumer genetics company that uses whole-genome sequencing and proprietary polygenic risk score models to sell at-home genetic tests, IVF embryo analysis software, and a $30,000 IVF concierge package to couples, IVF patients, and partner fertility clinics worldwide.
- Ownership category
- akta.pro rank
Nucleus industry classification
Industry- Product category
- Consumer Genomics and Genetic Testing
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)
- akta.pro secondary industries
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where Nucleus is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Nucleus business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Others
Revenue model
- Nucleus Preview (Direct-to-Consumer DNA Testing): At-home cheek-swab kits for whole-genome sequencing with carrier screening. Sold directly to consumers through the website. Price point in the low-hundreds of dollars for the at-home test kit.
- Nucleus Embryo: Software-based embryo analysis service allowing comparison of embryos across health and trait categories. Includes analysis for up to 20 embryo PGT files, two carrier screening DNA kits, and one genetic counseling session. Automatic updates to embryo analysis results as models improve.
- Nucleus IVF+: Comprehensive package combining Nucleus Embryo with IVF concierge services including facilitation with fertility clinics. Priced at approximately $30,000.
- Membership/Subscription: Annual membership renewal for ongoing access to results, automatic updates, and features. Membership renews annually on its anniversary date.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Nucleus Preview - At-home genetic testing for couples or individuals |
| One time/ perpetual license | Pay-as-you-go | Nucleus Embryo - Embryo genetic analysis software |
| One time/ perpetual license | Pay-as-you-go | Nucleus IVF+ - Comprehensive IVF embryo selection package |
| Subscription | Annual | Annual Membership |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Nucleus product offering
Product offeringCore offering
Nucleus provides direct-to-consumer genetic testing built on clinical-grade whole-genome sequencing, including at-home cheek-swab kits (Preview, Health) with carrier screening and polygenic risk scoring, as well as Nucleus Embryo and Nucleus IVF+ packages that compare IVF embryos across hereditary disease risks and traits for prospective parents. The company also operates Nucleus Labs, which develops the Origin family of polygenic prediction models and the Genetic Optimization Hub for research transparency.
Product overview
Nucleus offers a suite of consumer genomic health products centered on whole-genome sequencing and polygenic risk scoring. The core portfolio consists of Nucleus Preview and Nucleus Health (at-home genetic testing kits with carrier screening), Nucleus Embryo (IVF embryo analysis software), and Nucleus IVF+ (premium IVF concierge service). Supporting the product line, Nucleus Labs developed Origin, a family of nine AI-powered polygenic prediction models, and the Genetic Optimization Hub for research transparency. All services process genetic data through CLIA-certified laboratories and deliver results via digital reports accessible through the Nucleus platform.
Differentiator
Problem solved
Functional benefit
Brands
- Nucleus Health: At-home cheek-swab kit for whole-genome sequencing with carrier screening
- Nucleus Preview
- Nucleus Embryo
- Nucleus IVF+
- Origin
Products and services
- Nucleus Preview At-home cheek-swab kit for couples (or individuals) that performs clinical-grade whole-genome sequencing with carrier screening, allowing partners to sync results and assess hereditary disease risks before conception. Priced in the low hundreds of dollars.
- Nucleus Health At-home cheek-swab kit with whole-genome sequencing, comprehensive health insights and genetic risk assessments, processed by a CLIA-certified lab. In the U.S. it is physician-ordered and reviewed through an independent physician network, with digital reports delivered to the consumer.
- Nucleus Embryo Software-based embryo analysis service for IVF patients that compares up to 20 embryo PGT files across broad health and trait categories, screening for hereditary disorders, cancers, chronic conditions, and neurological/mental health risks. Includes two carrier screening DNA kits for biological parents and one genetic counseling session, with automatic result updates as models improve.
- Nucleus IVF+ Premium full-service package combining Nucleus Embryo analysis with IVF concierge services, including facilitation with fertility clinics and embryo ranking for predicted intelligence, disease risk, and physical traits such as eye color and height. Priced at approximately $30,000 and distributed through the IVF+ network of 160+ partner clinics globally.
- Origin Family of nine advanced polygenic prediction models that estimate human longevity and health outcomes from embryo DNA, described as the most predictive genetic models ever built for reproductive health applications. Available under license for non-commercial research and internal evaluation.
- Genetic Optimization Hub Public-facing Nucleus Labs hub where companies, labs, and researchers can open-weight and share the accuracy of their genetic optimization models, supporting transparency in polygenic score methodologies.
Quantifiable outcome
- Screens for over 2,000 genetic conditions and traits per embryo
- +3 more outcomes
Companies that use Nucleus
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Nucleus technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature4 records
Nucleus partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- Fertility Institute of HawaiicoreHawaii's largest IVF institution joined the Nucleus IVF+ Network. Provides advanced genetic embryo analysis for IVF patients, expanding access for local and international patients including those from Asia, Australia, and New Zealand.
- Southern California Reproductive Center (SCRC)corePasadena fertility clinic joined Nucleus IVF+ Network. Integrated advanced genetic testing into fertility services across four California locations. Offers carrier screening and embryo analysis for 2,000+ rare inherited conditions.
- Indira IVFcoreIndia-based IVF clinic partnership for embryo testing technology expansion to India. Part of broader international expansion strategy targeting Asian markets.
- Abu Ghosh Fertility GroupcoreMiddle East expansion partnership covering Saudi Arabia and Jordan. Enables embryo testing services in the region for disease risk prediction and trait analysis.
- CambreancoreAcquisition of AI-powered wearable health platform Cambrean. Accelerates Nucleus's shift toward combining genetic baselines with continuous biometric data for personalized health insights. Part of broader preventive health genomics repositioning.
- Bryan Johnson's Don't Die ProgramcorePartnership with Bryan Johnson's longevity program. Nucleus services integrated into the Don't Die lifestyle optimization platform. Positions Nucleus as part of premium longevity ecosystem.
- Neway FertilityminorNew York City fertility clinic partnered with Nucleus. Latest clinic to join the IVF+ network, bringing advanced genetic embryo analysis to NYC patients.
- Beverly Hills FertilityminorPremium Beverly Hills fertility clinic partnered with Nucleus for exclusive network launch. Represents high-end segment of fertility market.
- Columbia University (Dr. Dieter Egli lab)coreCo-authored research on base editing technology for human embryo gene editing. Committed to funding further studies on embryo editing. Positions Nucleus at the frontier of reproductive genetics research.
- HelpCureHDminorNonprofit partner committed to eradicating Huntington's disease. Part of Nucleus Cares program supporting families who need advanced reproductive care for medical reasons. HelpCureHD identifies and refers families to Nucleus services.
- Genomic PredictioncorePartnership (2025) for Nucleus Embryo product launch. Combined expertise in polygenic embryo screening. Note: Genomic Prediction filed lawsuit in 2025 against former employees for misappropriation of embryonic DNA sequencing technology.
Scale indicators6 records
Recent moves9 records
Expansion highlights6 records
Nucleus competitors and assessment
Company assessmentBroad incumbents
- Natera: Large publicly-traded reproductive and oncology genetics company offering PGT-A, carrier screening, and hereditary cancer testing. Competes with Nucleus in the IVF clinic channel via established reproductive health products.
- Sema4: Clinical genomic testing company providing reproductive health, hereditary cancer, and rare disease diagnostics. Comparable in clinical-grade genetic testing for reproductive and consumer health contexts.
- MyHeritage: Consumer genetics platform offering ancestry and health DNA tests globally. Comparable to Nucleus's DTC at-home kit business, though with deeper international reach and broader product portfolio.
- 23andMe: Largest consumer genetic testing brand in the U.S. Nucleus explicitly differentiates on whole-genome sequencing versus 23andMe's array-based genotyping. Both target health-conscious consumers seeking genetic insights.
- CooperSurgical (PGT): Major fertility and reproductive health company offering PGT-A services through fertility clinics globally. Comparable as an established channel for preimplantation genetic testing in the IVF market Nucleus targets.
Direct peers
- Genomic Prediction: Pioneer in polygenic embryo screening for IVF. Both a Nucleus partner (for the Nucleus Embryo launch) and a direct competitor offering PGT-P across similar clinical use cases including disease risk and trait prediction.
- Helix: DNA testing platform offering clinical-grade sequencing for health and wellness applications. Comparable on whole-exome/whole-genome sequencing infrastructure and consumer health focus.
- Orchid Health: Direct competitor in polygenic embryo screening for IVF patients. Offers whole-genome sequencing-based embryo analysis and is positioned alongside Nucleus as a category leader in PGT-P, frequently cited together in press coverage.
Emerging players
- InsideTracker: Personalized health and longevity platform integrating blood biomarkers, DNA, and wearable data. Comparable to Nucleus's strategic direction toward combining genetic baselines with continuous biometric monitoring.
- Function Health: Preventive health platform offering comprehensive bloodwork and diagnostics on a membership model. Directly comparable to Nucleus's post-Cambrean preventive health pivot combining genetic and biometric data.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Nucleus social profiles
Digital presenceNucleus compliance and trust
Trust signalCompliance2 records
Nucleus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nucleus leadership team
Management profileNumber of profiles
Profiles6 records
Nucleus subsidiaries and ownership
Company hierarchySubsidiaries1 record
Nucleus funding detail
Funding detailFunding overview
Funding rounds3 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nucleus M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nucleus
What does Nucleus do?
Nucleus provides direct-to-consumer genetic testing built on clinical-grade whole-genome sequencing, including at-home cheek-swab kits (Preview, Health) with carrier screening and polygenic risk scoring, as well as Nucleus Embryo and Nucleus IVF+ packages that compare IVF embryos across hereditary disease risks and traits for prospective parents. The company also operates Nucleus Labs, which develops the Origin family of polygenic prediction models and the Genetic Optimization Hub for research transparency.
Is Nucleus a public or private company?
Nucleus is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nucleus founded?
Nucleus was founded in 2021. It employs 11 to 50 people.
Where is Nucleus based?
Nucleus is headquartered in New York, United States, in the North America region.
How does Nucleus make money?
Four revenue lines are on record. Nucleus Preview (Direct-to-Consumer DNA Testing) is the primary driver. The others are nucleus Embryo, nucleus IVF+ and membership/Subscription.
Who are Nucleus's main competitors?
Broad incumbents on record are Natera, Sema4, MyHeritage, 23andMe and CooperSurgical (PGT). Direct peers are Genomic Prediction, Helix and Orchid Health. Emerging players are InsideTracker and Function Health.
Does Nucleus have an API?
Yes. Nucleus operates a public status API that provides JSON endpoints for checking system status. The API offers two GET endpoints: (1) /v3/summary.json returns overall status including page name, URL, status (UP), active incidents with impact levels, and active maintenance information; (2) /v3/components.json returns component-level status for services like the App (currently showing OPERATIONAL status). This API is read-only and serves the status page infrastructure using the Instatus service. Developer documentation is at status.mynucleus.com/en-us/public-api.
What industry is Nucleus in?
Nucleus's product category is Consumer Genomics and Genetic Testing. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.